Endofluke Oral Suspension Approved For Use In Dairy Cows

Endofluke 2.5L packshot Bimeda UK is pleased to announce that Endofluke 100mg Oral Suspension (VM No. 12597/4037) has now been approved for use in dairy cows, with a milk withdrawal period of 45 days + 48 hours. Endofluke is licensed for use in cattle and sheep and its active ingredient, triclabendazole (100mg/ml), is the only active proven to kill all three stages of liver fluke. Bimeda UK Sales Manager, Andrew Lane, commented, “This is great news for the UK’s dairy farmers. Endofluke has long been favoured by British & Northern Irish farmers as a liver fluke treatment, due to its ability to offer complete chronic and acute fluke control in both sheep and cattle. It is proven to be highly effective against early-immature, immature and adult liver fluke, and to now be able to extend these benefits to dairy cows, is fantastic news for the UK’s dairy farmers.” Bimeda’s Commercial Vet, Padraig Hyland, added, “We are extremely happy to be able to now provide this tried and trusted fluke treatment to the UK’s dairy farmers.” Endofluke is a POM-VPS product. Advice should be sought from the medicines prescriber before using the product. Use medicines responsibly. www.noah.co.uk For more information, see www.bimeda.co.uk or contact Bimeda UK Sales Manager Andrew Lane, on [email protected] or on 07917 208524.

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards